Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcellx, Inc. - Common Stock (NQ:ACLX)

71.97 +0.20 (+0.28%)
Streaming Delayed Price Updated: 12:42 PM EDT, Aug 22, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Arcellx, Inc. - Common Stock

Arcellx Provides Second Quarter 2025 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire
Arcellx Announces Its Participation at TD Cowen’s 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025
From Arcellx, Inc.
Via Business Wire
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients with Relapsed and/or Refractory Multiple Myeloma
From Arcellx, Inc.
Via Business Wire
Arcellx Provides First Quarter 2025 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors
From Arcellx, Inc.
Via Business Wire
Arcellx Provides Fourth Quarter and Year-End 2024 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire
Arcellx to Participate at the TD Cowen 45th Annual Health Care Conference
From Arcellx, Inc.
Via Business Wire
Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition
From Arcellx, Inc.
Via Business Wire
Arcellx Provides Third Quarter 2024 Financial Results and Business Highlights
From Arcellx, Inc.
Via Business Wire
Arcellx to Present Clinical Data for Its Phase 1 and iMMagine-1 Studies in Patients with Relapsed or Refractory Multiple Myeloma at the 66th ASH Annual Meeting and Exposition and Announces Progress in iMMagine-3 Study
From Arcellx, Inc.
Via Business Wire
Arcellx Provides Second Quarter 2024 Financial Results and Business Updates
From Arcellx, Inc.
Via Business Wire
Arcellx and Kite Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Arcellx, Inc.
Via Business Wire
Kite and Arcellx Continue Momentum with Advances in Anito-Cel Multiple Myeloma Program
From Gilead Sciences, Inc.
Via Business Wire
Arcellx Provides First Quarter 2024 Financial Results
From Arcellx, Inc.
Via Business Wire
Arcellx to Participate in Two Upcoming Investor Conferences
From Arcellx, Inc.
Via Business Wire
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
From Arcellx, Inc.
Via Business Wire
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
From Arcellx, Inc.
Via Business Wire
Kite and Arcellx Announce Expansion in Strategic Partnership
From Gilead Sciences, Inc.
Via Business Wire
Kite and Arcellx Close Agreement to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
From Gilead Sciences, Inc. and Arcellx, Inc.
Via Business Wire
Kite and Arcellx Announce Strategic Collaboration to Co-develop and Co-commercialize Late-stage Clinical CART-ddBCMA in Multiple Myeloma
From Gilead Sciences, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.